阿米福汀对局部晚期非小细胞肺癌患者肺功能及免疫功能的影响

Effect of Amifostine on Pulmonary Functions and Immune Functions in Patients with Locally Advanced Non-small Cell Lung Cancer

目的:分析阿米福汀用于局部晚期非小细胞肺癌放射治疗对患者肺功能及免疫功能的影响。方法:选择2017年1月—2019年1月于我院接受放疗的60例局部晚期非小细胞肺癌患者,根据随机数字表法分为对照组与治疗组,各30例。对照组实施放射治疗,治疗组在每次放疗前15 min使用阿米福汀(200~300mg/m^2),持续治疗6周后评价疗效,记录并比较两组治疗期间毒副反应、肺功能及免疫功能变化情况。结果:两组客观有效率比较差异无统计学意义(P> 0.05);治疗期间治疗组各毒副反应发生率低于对照组,差异有统计学意义(P <0.05);治疗结束时,治疗组用力肺活量(FVC)、第一秒用力呼气容积(FEV1)水平与治疗前比较,差异无统计学意义(P> 0.05),但均高于对照组,差异有统计学意义(P <0.05);治疗组CD3^+、CD4^+、CD4^+/CD8^+水平均较对照组升高,CD8^+水平较对照组降低,差异有统计学意义(P <0.05)。结论:晚期局部非小细胞肺癌患者放疗期间使用阿米福汀,利于减少因放疗带来的毒副反应,提高免疫功能,且不会影响放疗效果及肺功能,值得推广应用。

Objective:To analyze the effect of amifostine on pulmonary functions and immune functions in patients with locally advanced non-small cell lung cancer.Methods:60 patients with locally advanced non-small cell lung cancer who underwent radiotherapy in our hospital from January 2017 to January 2019 were selected and randomly divided into a control group and a treatment group,30 cases each.The patients in the control group were given radiotherapy,and the patients in the treatment group were treated with amifostine(200~300 mg/m^2)at 15 min before each radiotherapy.The therapeutic effect was evaluated after 6 weeks of continuous treatment.The toxicity and other adverse reactions and changes in pulmonary functions and immune functions during the treatment were recorded and compared between the two groups.Results:There was no statistically significant difference in the objective effective rate between the two groups(P>0.05).The incidence of toxicity and other side reactions during the treatment in the treatment group was lower than that in the control group,with statistically signi?cant difference(P<0.05).The levels of forced vital capacity(FVC)and forced expiratory volume in the?rst second(FEV1)in the treatment group at the end of treatment were not signi?cantly different from those before treatment(P>0.05),but the levels were higher than those in the control group,with statistically signi?cant differences(P<0.05).The levels of CD3^+,CD4^+and CD4^+/CD8^+in the treatment group were higher than those in the control group,while the level of CD8^+was lower than that in the control group,with statistically signi?cant differences(P<0.05).Conclusion:Amifotine used during radiotherapy in the patients with advanced local non-small cell lung cancer can reduce the toxicity and side effects caused by radiotherapy and improve immune functions,and does not affect the effect of radiotherapy and pulmonary functions,which is worth popularizing and applying.